Literature DB >> 30111623

How to Determine the Role of the Microbiome in Drug Disposition.

Jordan E Bisanz1, Peter Spanogiannopoulos1, Lindsey M Pieper1, Annamarie E Bustion1, Peter J Turnbaugh2.   

Abstract

With a paradigm shift occurring in health care toward personalized and precision medicine, understanding the numerous environmental factors that impact drug disposition is of paramount importance. The highly diverse and variant nature of the human microbiome is now recognized as a factor driving interindividual variation in therapeutic outcomes. The purpose of this review is to provide a practical guide on methodology that can be applied to study the effects of microbes on the absorption, distribution, metabolism, and excretion of drugs. We also highlight recent examples of how these methods have been successfully applied to help build the basis for researching the intersection of the microbiome and pharmacology. Although in vitro and in vivo preclinical models are highlighted, these methods are also relevant in late-phase drug development or even as a part of routine after-market surveillance. These approaches will aid in filling major knowledge gaps for both current and upcoming therapeutics with the long-term goal of achieving a new type of knowledge-based medicine that integrates data on the host and the microbiome.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30111623     DOI: 10.1124/dmd.118.083402

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  Epithelial delamination is protective during pharmaceutical-induced enteropathy.

Authors:  Scott T Espenschied; Mark R Cronan; Molly A Matty; Olaf Mueller; Matthew R Redinbo; David M Tobin; John F Rawls
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-07       Impact factor: 11.205

2.  Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives.

Authors:  Ling Zou; Peter Spanogiannopoulos; Lindsey M Pieper; Huan-Chieh Chien; Wenlong Cai; Natalia Khuri; Joshua Pottel; Bianca Vora; Zhanglin Ni; Eleftheria Tsakalozou; Wenjun Zhang; Brian K Shoichet; Kathleen M Giacomini; Peter J Turnbaugh
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-22       Impact factor: 11.205

3.  Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism.

Authors:  Peter Spanogiannopoulos; Than S Kyaw; Ben G H Guthrie; Patrick H Bradley; Joyce V Lee; Jonathan Melamed; Ysabella Noelle Amora Malig; Kathy N Lam; Daryll Gempis; Moriah Sandy; Wesley Kidder; Erin L Van Blarigan; Chloe E Atreya; Alan Venook; Roy R Gerona; Andrei Goga; Katherine S Pollard; Peter J Turnbaugh
Journal:  Nat Microbiol       Date:  2022-09-22       Impact factor: 30.964

4.  Fundamental dietary specialisation explains differential use of resources within a koala population.

Authors:  Karen J Marsh; Michaela D J Blyton; William J Foley; Ben D Moore
Journal:  Oecologia       Date:  2021-06-17       Impact factor: 3.225

5.  Modulation of Gut Microbiota by Glucosamine and Chondroitin in a Randomized, Double-Blind Pilot Trial in Humans.

Authors:  Sandi L Navarro; Lisa Levy; Keith R Curtis; Johanna W Lampe; Meredith A J Hullar
Journal:  Microorganisms       Date:  2019-11-23

Review 6.  Intestinal Microbiota-Associated Metabolites: Crucial Factors in the Effectiveness of Herbal Medicines and Diet Therapies.

Authors:  Yiliang Wang; Shurong Qin; Jiaoyan Jia; Lianzhou Huang; Feng Li; Fujun Jin; Zhe Ren; Yifei Wang
Journal:  Front Physiol       Date:  2019-10-29       Impact factor: 4.566

Review 7.  The Microbiome and the Gut-Liver-Brain Axis for Central Nervous System Clinical Pharmacology: Challenges in Specifying and Integrating In Vitro and In Silico Models.

Authors:  Kyle G Hawkins; Caleb Casolaro; Jacquelyn A Brown; David A Edwards; John P Wikswo
Journal:  Clin Pharmacol Ther       Date:  2020-05-29       Impact factor: 6.875

Review 8.  Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response.

Authors:  Jose U Scher; Renuka R Nayak; Carles Ubeda; Peter J Turnbaugh; Steven B Abramson
Journal:  Nat Rev Rheumatol       Date:  2020-03-10       Impact factor: 32.286

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.